Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
229 hedge funds and large institutions have $2.8B invested in Clovis Oncology, Inc. in 2017 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 77 increasing their positions, 55 reducing their positions, and 17 closing their positions.
406% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 17
66% more capital invested
Capital invested by funds: $1.68B → $2.8B (+$1.12B)
40% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 55
37% more funds holding
Funds holding: 167 → 229 (+62)
36% more call options, than puts
Call options by funds: $100M | Put options by funds: $73.6M
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$185M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$80.2M |
| 4 |
D.E. Shaw & Co
New York
|
+$56.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$49.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$84.9M |
| 2 |
PC
PointState Capital
New York
|
-$69.7M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$50.6M |
| 4 |
SC
Samlyn Capital
New York
|
-$40.1M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$39.4M |
CLVS Hedge Fund Activity: Q1 2017 in Review
229 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2017, worth a combined $2.8B — up 66% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new CLVS positions and 17 closed out — a net gain of 69 holders — while 77 added to existing stakes and 55 trimmed.
The largest buyer was BlackRock, adding an estimated $185M. The largest seller was Consonance Capital Management, cutting an estimated $84.9M.
- 229 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2017, up from 167 in Q4 2016.
- Funds reported $2.8B of Clovis Oncology, Inc. stock for Q1 2017, up 66% quarter-over-quarter.
- 86 funds opened new Clovis Oncology, Inc. positions in Q1 2017 and 17 closed out, a net change of +69 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2017 was BlackRock, an estimated $185M added.
- The largest Clovis Oncology, Inc. seller in Q1 2017 was Consonance Capital Management, an estimated $84.9M sold.
Based on aggregated 13F filings for Q1 2017.